{"id":4013,"date":"2025-06-27T12:29:23","date_gmt":"2025-06-27T09:29:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4013"},"modified":"2025-06-27T12:29:24","modified_gmt":"2025-06-27T09:29:24","slug":"entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/zh\/entrada-therapeutics-begins-clinical-trials-in-europe-for-exon-44-and-exon-45-skipping-therapies\/","title":{"rendered":"Entrada Therapeutics \u5728\u6b27\u6d32\u5f00\u59cb\u8fdb\u884c\u5916\u663e\u5b50 44 \u548c\u5916\u663e\u5b50 45 \u8df3\u8dc3\u7597\u6cd5\u4e34\u5e8a\u8bd5\u9a8c"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics \u5df2\u5728\u6b27\u6d32\u6b63\u5f0f\u542f\u52a8\u9488\u5bf9\u5916\u663e\u5b50 44 \u548c\u5916\u663e\u5b50 45 \u7684\u521b\u65b0\u5916\u663e\u5b50\u8df3\u8dc3\u7597\u6cd5\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8fd9\u662f\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7 (DMD) \u6cbb\u7597\u9886\u57df\u7684\u4e00\u4e2a\u91cd\u8981\u91cc\u7a0b\u7891\u3002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u8fd9\u4e9b\u5728\u7814\u7597\u6cd5\u65e8\u5728\u89e3\u51b3\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7 (DMD) \u60a3\u8005\u7684\u7279\u5b9a\u57fa\u56e0\u7a81\u53d8\uff0c\u76ee\u6807\u662f\u6062\u590d\u808c\u8425\u517b\u4e0d\u826f\u86cb\u767d\u7684\u751f\u6210\u5e76\u6539\u5584\u4e34\u5e8a\u7597\u6548\u3002\u8fd9\u4e9b\u8bd5\u9a8c\u7684\u542f\u52a8\u5f70\u663e\u4e86 Entrada \u81f4\u529b\u4e8e\u63a8\u8fdb\u7cbe\u51c6\u57fa\u56e0\u533b\u5b66\u53d1\u5c55\u4ee5\u53ca\u6269\u5927\u5168\u7403\u7f55\u89c1\u795e\u7ecf\u808c\u8089\u75be\u75c5\u65b0\u578b\u7597\u6cd5\u53ef\u53ca\u6027\u7684\u51b3\u5fc3\u3002\u2014\u2014 \u9605\u8bfb\u66f4\u591a\uff1a <a href=\"https:\/\/dmdwarrior.com\/zh\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u4ec0\u4e48\u662f\u5916\u663e\u5b50\u8df3\u8dc3\uff1f\u5b83\u662f\u5982\u4f55\u5de5\u4f5c\u7684\uff1f<\/a> \u2013<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u76ee\u5f55<\/h2><nav><ul><li><a href=\"#entrada-exon-44-skipping-nct-07037862\">Entrada \u5916\u663e\u5b50 44 \u8df3\u8dc3 \u2013 NCT07037862 \u2013<\/a><\/li><li><a href=\"#entrada-exon-45-skipping-nct-07038824\">Entrada \u5916\u663e\u5b50 45 \u8df3\u8dc3 \u2013 NCT07038824 \u2013<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-44-skipping-nct-07037862\">Entrada \u5916\u663e\u5b50 44 \u8df3\u8dc3 \u2013 NCT07037862 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u8fd9\u662f\u4e00\u9879\u9488\u5bf9\u60a3\u6709\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7 (DMD)\uff08\u4e00\u79cd\u7f55\u89c1\u9057\u4f20\u75c5\uff09\u7684\u53d7\u8bd5\u8005\u7684\u8bd5\u9a8c\u836f\u7269 ENTR-601-44 \u7814\u7a76\u3002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u5b66\u4e60\u5f00\u59cb\u65f6\u95f4\uff08\u9884\u8ba1\uff09<\/strong>: 2025-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u5c0f\u5b66\u5b8c\u6210\u60c5\u51b5\uff08\u9884\u8ba1\uff09<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u7814\u7a76\u5b8c\u6210\u60c5\u51b5\uff08\u9884\u8ba1\uff09<\/strong>: 2029-03-28<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u53c2\u4e0e\u4eba\u6570\uff08\u9884\u8ba1\uff09<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u4f4d\u7f6e<\/strong>\uff1a\u6bd4\u5229\u65f6\u3001\u610f\u5927\u5229\u3001\u897f\u73ed\u7259\u3001\u82f1\u56fd\u3002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u9002\u5408\u5b66\u4e60\u7684\u5e74\u9f84<\/strong>\uff1a4\u5c81\u81f320\u5c81\uff08\u513f\u7ae5\u3001\u6210\u4eba\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u4e3b\u8981\u7eb3\u5165\u548c\u6392\u9664\u6807\u51c6\u3002\u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07037862\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07037862<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"entrada-exon-45-skipping-nct-07038824\">Entrada \u5916\u663e\u5b50 45 \u8df3\u8dc3 \u2013 NCT07038824 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u8fd9\u662f\u4e00\u9879\u9488\u5bf9\u60a3\u6709\u675c\u6c0f\u808c\u8425\u517b\u4e0d\u826f\u75c7 (DMD)\uff08\u4e00\u79cd\u7f55\u89c1\u9057\u4f20\u75c5\uff09\u7684\u53d7\u8bd5\u8005\u7684\u8bd5\u9a8c\u836f\u7269 ENTR-601-45 \u7814\u7a76\u3002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u5b66\u4e60\u5f00\u59cb\u65f6\u95f4\uff08\u9884\u8ba1\uff09<\/strong>: 2025-09-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u5c0f\u5b66\u5b8c\u6210\u60c5\u51b5\uff08\u9884\u8ba1\uff09<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u7814\u7a76\u5b8c\u6210\u60c5\u51b5\uff08\u9884\u8ba1\uff09<\/strong>: 2029-03-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u53c2\u4e0e\u4eba\u6570\uff08\u9884\u8ba1\uff09<\/strong>: 24<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u4f4d\u7f6e<\/strong>\uff1a\u6bd4\u5229\u65f6\u3001\u610f\u5927\u5229\u3001\u8377\u5170\u3001\u897f\u73ed\u7259\u3001\u82f1\u56fd\u3002<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u9002\u5408\u5b66\u4e60\u7684\u5e74\u9f84<\/strong>\uff1a4\u5c81\u81f320\u5c81\uff08\u513f\u7ae5\u3001\u6210\u4eba\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u4e3b\u8981\u7eb3\u5165\u548c\u6392\u9664\u6807\u51c6\u3002\u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07038824\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07038824<\/a> \u2013<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/dmdwarrior.com\/zh\/tag\/entrada-therapeutics\/\">\u4e86\u89e3\u6709\u5173 Entrada Therapeutics \u7684\u66f4\u591a\u4fe1\u606f<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics has officially launched clinical trials in Europe for its innovative exon skipping therapies targeting Exon 44 and Exon 45\u2014marking a significant milestone in the treatment of Duchenne muscular dystrophy (DMD). These investigational therapies are designed to address specific genetic mutations in DMD patients, with the goal of restoring dystrophin production and improving clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4021,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[242,233,234,84,246,319,178],"class_list":["post-4013","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trials","tag-entrada","tag-entrada-therapeutics","tag-europe","tag-exon-44-skipping-therapies","tag-exon-45-skipping-therapy","tag-exon-skipping-therapies"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/4013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/comments?post=4013"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/4013\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media\/4021"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media?parent=4013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/categories?post=4013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/tags?post=4013"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}